ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates (ADCs), has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. CEO Ameet Mallik will engage in a fireside chat scheduled for Thursday, February 6, 2025, at 2:00 p.m. ET.
The presentation will be accessible through a live webcast on the Events & Presentations page of ADC Therapeutics' investor relations website section. Interested parties who cannot attend the live session can access a replay of the webcast, which will remain available for approximately 30 days following the event.
ADC Therapeutics (NYSE: ADCT), un leader commerciale nel settore dei conjugati di farmaci ad anticorpi (ADC), ha annunciato la sua partecipazione alla prossima Guggenheim SMID Cap Biotech Conference. Il CEO Ameet Mallik parteciperà a una chiacchierata informale programmata per giovedì 6 febbraio 2025, alle 14:00 ET.
La presentazione sarà accessibile tramite un webcast in diretta sulla pagina Eventi & Presentazioni del sito web delle relazioni con gli investitori di ADC Therapeutics. Le parti interessate che non possono partecipare alla sessione dal vivo potranno accedere a una registrazione del webcast, che rimarrà disponibile per circa 30 giorni dopo l'evento.
ADC Therapeutics (NYSE: ADCT), un líder comercial en conjugados de fármacos con anticuerpos (ADCs), ha anunciado su participación en la próxima Guggenheim SMID Cap Biotech Conference. El CEO Ameet Mallik participará en una charla junto a la chimenea programada para el jueves 6 de febrero de 2025, a las 14:00 ET.
La presentación estará disponible a través de una transmisión en vivo en la página de Eventos y Presentaciones del sitio web de relaciones con inversores de ADC Therapeutics. Las partes interesadas que no puedan asistir a la sesión en vivo podrán acceder a una repetición de la transmisión, que estará disponible durante aproximadamente 30 días después del evento.
ADC Therapeutics (NYSE: ADCT)는 항체 약물 접합체(ADC) 분야의 상장된 선두주자로서 다가오는 구겐하임 SMID 캡 바이오테크 컨퍼런스에 참여한다고 발표했습니다. CEO 아미트 말릭이 2025년 2월 6일 목요일 오후 2시 ET에 예정된 파이어사이드 채팅에 참여합니다.
발표는 ADC Therapeutics의 투자자 관계 웹사이트의 이벤트 및 발표 페이지를 통해 라이브 웹캐스트로 시청할 수 있습니다. 생중계에 참석할 수 없는 관심 있는 분들은 이벤트 이후 약 30일 동안 반복 시청을 할 수 있습니다.
ADC Therapeutics (NYSE: ADCT), un leader commercial dans le domaine des conjugués d'anticorps médicaments (ADCs), a annoncé sa participation à la prochaine Conférence Guggenheim SMID Cap Biotech. Le PDG Ameet Mallik participera à une discussion informelle prévue pour jeudi 6 février 2025, à 14h00 ET.
La présentation sera accessible via un webinaire en direct sur la page Événements & Présentations du site des relations investisseurs d'ADC Therapeutics. Les parties intéressées qui ne peuvent pas assister à la session en direct pourront accéder à une rediffusion du webinaire, qui sera disponible pendant environ 30 jours après l'événement.
ADC Therapeutics (NYSE: ADCT), ein führendes Unternehmen im Bereich Akkordierte Antikörper-Arzneimittel (ADCs), hat seine Teilnahme an der kommenden Guggenheim SMID Cap Biotech Conference bekannt gegeben. CEO Ameet Mallik wird an einem Fireside Chat teilnehmen, der für Donnerstag, den 6. Februar 2025, um 14:00 Uhr ET angesetzt ist.
Die Präsentation wird über einen Live-Webcast auf der Seite Veranstaltungen & Präsentationen der Investoren-Relations-Website von ADC Therapeutics zugänglich sein. Interessierte, die nicht an der Live-Sitzung teilnehmen können, haben die Möglichkeit, eine Wiederholung des Webcasts anzusehen, die etwa 30 Tage nach der Veranstaltung verfügbar bleibt.
- None.
- None.
A live webcast of the presentation will be available via the Events & Presentations page in the IR section of the ADC Therapeutics website. A replay of the webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
CONTACTS:
Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-participate-in-the-guggenheim-smid-cap-biotech-conference-302363877.html
SOURCE ADC Therapeutics SA
FAQ
When is ADC Therapeutics (ADCT) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch ADC Therapeutics' presentation at the Guggenheim Conference?
How long will the replay of ADCT's Guggenheim Conference presentation be available?
Who will represent ADC Therapeutics at the Guggenheim SMID Cap Biotech Conference 2025?
